Articles

Cranbury, NJ – Starting October 13, the Association for Value-Based Cancer Care (AVBCC) will present its 10th Annual Summit as a 10-week series with approximately 30 WEBside chats. The 10th Association for Value-Based Cancer Care Summit & Education WEBside chats will feature top influencers; future trends; balanced opinions; real-time, real-world information; and unfiltered discussions. Each chat will run for approximately 90 minutes on alternating Tuesday, Wednesday, Thursday and/or Friday sessions delivered at 8:00 am ET and rebroadcast at 4:30 pm PT.

David DeRemer, PharmD, BCOP, FCCP, FHOPA, Clinical Associate Professor, University of Florida College of Pharmacy, shares insights about cancer drugs and COVID-19 in this interview that followed a segment of the Association for Value-Based Cancer Care (AVBCC) webinar series COVID-19 Recovery, the Road Ahead, in which he recently took part.

When oncology practices, ranging from small community clinics to larger hospital-based programs, were required to adapt their systems virtually overnight in response to the COVID-19 health crisis, almost no one anticipated that these would be long-term changes. However, as September approaches with no end in sight, it has become clear that oncologists will need to adapt revenue cycle management to long-term pandemic-related changes.

As many full-service hospitals and health systems remain overwhelmed due to the COVID-19 pandemic, community cancer providers have been able to offer certain services to patients that may not be available at other institutions. How have these providers adapted to meet patients’ changing needs, and how are they keeping their doors open under unprecedented pressure?

From shuttered laboratory experiments and interrupted clinical trial enrollments to a “shadow curve” of delayed cancer diagnoses, comprehensive cancer centers and integrated delivery networks (IDNs) across the country continue to grapple with the fallout from COVID-19.

One of the most significant questions for payers in the COVID-19 health ecosystem is, “Will reimbursement parity for telehealth services continue?” Leading representatives of major managed care organizations debate the prospects.